Skip to content
Homepage
Clinic directory

Clinics in Bellevue, Wisconsin

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Bellevue, WI

Stem Cell Therapy clinics in Bellevue

Bellevue supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Overlake Medical Center and nearby University of Washington Medicine, and stem cell practice in the area spans downtown Bellevue, the Spring District, and Medina border. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Washington regulates physician practice through the Washington Medical Commission. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. Seattle's proximity to Fred Hutchinson Cancer Center and the University of Washington produces strong academic trial infrastructure. The 4 Bellevue clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Washington Medical Commission licensure checks.

No clinics found

Try adjusting your filters or search terms

Reset all filters

Regulatory context

A note on Wisconsin's stem cell therapy rules.

Wisconsin cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Wisconsin for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Wisconsin hosts substantial academic regenerative medicine research at UW-Madison.

  • Wisconsin Medical Practice Act, Wisconsin Statutes Chapter 448
    Establishes physician licensure and discipline through the Wisconsin Medical Examining Board.
  • Wisconsin Pharmacy Practice Act, Wisconsin Statutes Chapter 450
    Regulates compounding pharmacies aligned with federal 503A and 503B standards.
  • Wisconsin Deceptive Trade Practices Act, Wisconsin Statutes Section 100.18
    Empowers the Department of Agriculture, Trade and Consumer Protection and private plaintiffs to pursue deceptive marketing claims against providers making unsupported clinical claims.

The FDA has corresponded with Wisconsin providers offering cellular therapies, and warning letters have been issued to regional clinics. The Wisconsin Medical Examining Board has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. Wisconsin's Department of Agriculture, Trade and Consumer Protection and the Attorney General can pursue deceptive marketing under Wis Stat Section 100.18. UW-Madison operates compliant IND-based regenerative research programs.

Sources: fda.gov · dsps.wi.gov · doj.state.wi.us

Stem Cell Therapy in Bellevue, answered.

Most stem cell therapies at private Bellevue clinics are not FDA-approved. The FDA has approved certain hematopoietic stem cell products for blood and immune disorders, but stem cell injections for orthopedic, neurological, or longevity use are generally investigational. They require a Biologics License or an active Investigational New Drug authorization, or they must qualify as Section 361 minimally manipulated and homologous-use products under 21 CFR Part 1271. Washington regulates physician practice through the Washington Medical Commission.

In the Bellevue metro, single-joint autologous bone marrow or adipose injections typically run $4,000 to $12,000 per session. Systemic IV protocols using allogeneic umbilical cord or Wharton's jelly products range $8,000 to $20,000, and full multi-session protocols can reach $15,000 to $40,000. Exosome add-ons range $3,500 to $7,500. Insurance rarely covers these treatments because the FDA classifies most protocols as investigational.

Autologous stem cells come from your own body, usually harvested from bone marrow aspirate or adipose tissue and reinjected the same day. When minimally manipulated and used for homologous function, they often fall under FDA Section 361, which does not require pre-market approval. Allogeneic stem cells come from a donor source, most commonly umbilical cord blood or Wharton's jelly, and are generally classified as Section 351 biologics that require an active Investigational New Drug authorization. Bellevue clinic offerings span both categories, so ask which classification applies before treatment.

Yes. Research programs at Overlake Medical Center and nearby University of Washington Medicine periodically run FDA-authorized stem cell trials across orthopedics, neurology, cardiology, and oncology. Search clinicaltrials.gov and filter by Bellevue or the broader metro to see active recruiting studies. Trial participation is typically low-cost or free compared to commercial protocols and includes structured follow-up with imaging and lab monitoring.

Verify physician licensure through the Washington Medical Commission and confirm the clinic's NPI number through the NPPES registry. Check the FDA warning letter database for the clinic name and the HHS Office of Inspector General exclusion list. Ask whether the treatment is Section 361 or Section 351, whether the clinic operates under an Investigational New Drug authorization for allogeneic or expanded products, and whether adverse events are tracked. Ask specifically about compliance with federal 21 CFR 1271.

Treatment guide

Learn about Stem Cell Therapy

What it is, how it works, and what to expect.

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology